News | Prostate Cancer | June 14, 2018

Hitachi Medical Systems Europe Named Imaging Supplier for London Prostate Cancer Program

Hitachi to supply Arietta ultrasound and BiopSee systems to improve prostate cancer diagnosis in new RAPID program

Hitachi Medical Systems Europe Named Imaging Supplier for London Prostate Cancer Program

June 14, 2018 — Hitachi Medical Systems Europe has been awarded the contract to supply six ultrasound systems as part of the RAPID program to improve prostate cancer diagnosis across South West London. In addition to the six high-resolution Arietta ultrasound systems, the contract also includes six BiopSee image-guided fusion biopsy systems from MedCom (for which Hitachi is a European distributor) to be installed at three major hospitals. Using the two systems together will allow providers to combine multiparametric magnetic resonance imaging (mp-MRI) data with real-time ultrasound, reducing unnecessary biopsies and providing accurate targeting while reducing the number of samples needed.

The pilots for the RAPID (Rapid Assessment Prostate Imaging and Diagnosis) program have been developed through funding from RM Partners, the Cancer Alliance for west London hosted by The Royal Marsden. Three trusts are piloting RAPID – Epsom and St Helier University Hospitals NHS Trust, Imperial College Healthcare NHS Trust, and St George’s University Hospitals NHS Foundation Trust.

The RAPID approach involves the patient having an mp-MRI scan in the morning and reported immediately. If it shows areas of abnormality, the patient will then undergo a transperineal ultrasound fusion biopsy, all within the same day.

The transperineal approach, in which samples are taken through the perineum rather than the rectum, confers a comparatively low risk of sepsis, and can obviate the need for broad spectrum antibiotics and the possible development of antibiotic resistance.

Hashim Ahmed, professor and chair of urology, Imperial College London, said, “After trialling various systems on the market we felt that the Hitachi Arietta and MedCom BiopSee combination offered us the best in high-resolution imaging together with precise, accurate needle placement and an easy streamlined fusion software interface. This will help deliver a faster diagnosis and treatment for prostate cancer and reduce waiting times. The safer transperineal biopsy route will also reduce infection and life-threatening sepsis rates.”

The BiopSee system fuses the mp-MRI images with the Hitachi ultrasound images in real-time, allowing highly accurate placement of the biopsy needle in the prostate to target the tumour with exceptional precision. Three-dimensional ultrasound image acquisition, rigid/elastic fusion capabilities together with precise stepper tracking and reporting software deliver an exceptional diagnostic platform supporting the RAPID programme in London.

BiopSee records and stores the location of each tissue sample. This provides comprehensive documentation and reporting of biopsy core locations for accurate management of patients requiring further treatment and therapy planning in cryotherapy, brachytherapy, high intensity focused ultrasound (HIFU), radiofrequency (RF) or other treatment programmes.

Prostate cancer diagnosis has become a national health priority in the U.K., with Prime Minister Theresa May announcing in April the government’s £75m prostate cancer drive to be administered via the National Institute for Health Research clinical research network. This initiative will see 40,000 men recruited for research into the disease, which kills more than 11,000 a year and causes great anxiety and sometimes suffering for the 47,000 men who get a diagnosis.

For more information: www.hitachi-medical-systems.eu

Related Content

A 3-D ultrasound system provides an effective, noninvasive way to estimate blood flow that retains its accuracy across different equipment, operators and facilities, according to a study published in the journal Radiology.

Volume flow as a function of color flow gain (at a single testing site). For each row the color flow c-plane and the computed volume flow are shown as a function of color flow gain. The c-plane is shown for four representative gain levels, whereas the computed volume flow is shown for 12–17 steps across the available gain settings. Flow was computed with (solid circles on the graphs) and without (hollow circles on the graphs) partial volume correction. Partial volume correction accounts for pixels that are only partially inside the lumen. Therefore, high gain (ie, blooming) does not result in overestimation of flow. Systems 1 and 2 converge to true flow after the lumen is filled with color pixel. System 3 is nearly constant regarding gain and underestimates the flow by approximately 17%. Shown are mean flow estimated from 20 volumes, and the error bars show standard deviation. Image courtesy of the journal Radiology

News | Ultrasound Imaging | July 01, 2020
July 1, 2020 — A 3-D ultrasound
Researchers reviewed results of prostate biopsies on over 3,400 men who had targets identified on prostate MRI and found that the positive predictive value of the test for prostate cancer was highly variable at different sites
News | Prostate Cancer | July 01, 2020
July 1, 2020 — Prostate MRI is an emerging technology used to identify and guide treatment for...
Diffusion tractography uses the movement of water molecules to identify tracts that connect different parts of the brain. It can be used to pinpoint the part of the thalamus to treat with focused ultrasound. Image courtesy of UT Southwestern Medical Center

Diffusion tractography uses the movement of water molecules to identify tracts that connect different parts of the brain. It can be used to pinpoint the part of the thalamus to treat with focused ultrasound. Image courtesy of UT Southwestern Medical Center

News | Magnetic Resonance Imaging (MRI) | June 15, 2020
June 15, 2020 — Recently developed magneti...
 Samsung announced the immediate availability of the RS85 Prestige, the latest addition to the company’s portfolio of ultrasound systems.
News | Ultrasound Imaging | June 11, 2020
June 11, 2020 — Samsung announced the immediate availability of the ...
In new QuickPoLL survey on imaging during the pandemic, responses were tallied from around 170 radiology administrators and business managers, who are part of an imagePRO panel created by The MarkeTech Group (TMTG), regarding the effects of COVID-19 on their business. TMTG is a research firm specializing in the medical device, healthcare and pharmaceutical industries.
Feature | Coronavirus (COVID-19) | June 09, 2020 | By Melinda Taschetta-Millane
Although it is likely that existing ultrasound systems will be repurposed to treat COVID-19 patients, growth is still expected as companies plan to ramp up production. The ultrasound systems market will therefore outpace other diagnostic imaging such as computed tomography (CT) and magnetic resonance imaging (MRI). Leading data and analytics company GlobalData forecasts the market will reach $6bn by 2028, but increased usage due to COVID-19 is anticipated have a tangible effect.
News | Ultrasound Imaging | June 05, 2020
June 5, 2020 — Although it is likely that existing...
The Philips Lumify point-of-care ultrasound (POCUS) system assessing a patient in the emergency room combined with telehealth to enable real-time collaboration with other physicians.

The Philips Lumify point-of-care ultrasound (POCUS) system assessing a patient in the emergency room combined with telehealth to enable real-time collaboration with other physicians.

News | Coronavirus (COVID-19) | May 26, 2020
May 26, 2020  — Philips Healthcare recently received 510(k) clearance from the U.S.